All In Biotech

Drug Trial Radar · NCT05762107

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

A Phase 2a Randomized, Double-blind, Placebo-controlled, Multiple-dose, Crossover Study of the Effect of ZT-01 on Frequency of Nocturnal Hypoglycemia in Type 1 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

186

Planned (sponsor's estimate)

Start

Jul 28, 2023

Primary completion

Dec 2026

Study completion May 2027

Sponsor

Lead sponsor
Zucara Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Mar 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the effect of the study drug (ZT-01) on low blood sugar (hypoglycemia) in adults with type 1 diabetes (T1D) who have been having low blood sugars ("hypos") at night. ZT-01 increases the amount of a hormone called glucagon during low blood sugar, and this may help prevent the occurrence of hypos. The main questions this trial aims to answer are whether ZT-01 lowers the number of hypos happening at night, and what its effects are on blood sugar levels. The safety of ZT-01 will also be measured. Participants will be asked to wear a study-provided continuous glucose monitor (CGM) during two 4-week periods when they will self-inject the study drug before bed. They will get ZT-01 at one of three dose levels during one period, and placebo (which looks like the study drug but doesn't contain the active ingredient) during the other. Neither the participant nor the study site will know what they are receiving during each treatment period or see data from the CGM. The participant will continue to use their usual methods of measuring blood sugar (including their personal CGM) and giving insulin during the study. The participant will be asked to complete a short diary each evening, and will be asked to upload the CGM data to a study phone every day. If a participant uses their own CGM and is willing to share information on how often they have low blood sugar with the study site at the first visit to see if they meet study entry requirements, they will have 6 study visits, 2 study phone calls, and be in the study for about 16 weeks. If they don't use CGM or don't want to share their information, then they will be asked to wear a study CGM for an extra 4 weeks to find out how many low blood sugars they have, and will have an extra visit. Study participants will be asked to give blood and urine for testing to see whether they meet the requirements to enter the study, and at the start and end of each treatment period to see if the study treatment has any effects. They will also have their blood pressure and temperature taken at each study visit, and have an ECG at 4 visits to measure the electrical activity of their heart. Some participants will be asked to also take part in a sub-study where their blood level of ZT-01 and glucagon is measured, after the first and last dose. They will be asked to stay at the study site overnight for each set of measurements (4 in total).

Conditions

  • Type 1 Diabetes Mellitus With Hypoglycemia

Interventions

  • PlaceboDrug

    Subject receives Placebo by subcutaneous injection daily for 28 days

  • ZT-01, 7 mgDrug

    Subject receives ZT-01 7 mg by subcutaneous injection daily for 28 days

  • ZT-01, 15 mgDrug

    Subject receives ZT-01 15 mg by subcutaneous injection daily for 28 days

  • ZT-01, 22 mgDrug

    Subject receives ZT-01 22 mg by subcutaneous injection daily for 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of nocturnal hypoglycemiaTime frame: During each 28 day treatment period

Locations

46 sites in 2 countries. Site status is shown where the registry gives one.

  • Kirklin Clinic of UAB Hospital-Endocrinology/Diabetes Clinic

    Birmingham, Alabama · Recruiting

  • Medical Investigations Indications Inc.

    Little Rock, Arkansas · Recruiting

  • Headlands Research

    Escondido, California · Recruiting

  • USC Keck Medicine Eastside Center for Diabetes

    Los Angeles, California · Recruiting

  • LCGK Research

    San Carlos, California · Terminated

  • Barbara Davis Center for Diabetes

    Aurora, Colorado · Recruiting

  • Yale University - Diabetes Research Office

    New Haven, Connecticut · Recruiting

  • East Coast Institute for Research LLC

    Jacksonville, Florida · Recruiting

  • Suncoast Clinical Research

    New Port Richey, Florida · Recruiting

  • Hanson Diabetes Center

    Port Charlotte, Florida · Recruiting

  • University of South Florida Diabetes & Endocrinology Clinic

    Tampa, Florida · Recruiting

  • Metabolic Research Institute

    West Palm Beach, Florida · Recruiting

  • Atlanta Diabetes Associates

    Atlanta, Georgia · Recruiting

  • Physicians Research Associates LLC

    Lawrenceville, Georgia · Recruiting

  • East Coast Institute for Research

    Macon, Georgia · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • IU Health University Hospital

    Indianapolis, Indiana · Recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • Ochsner Clinic Foundation

    New Orleans, Louisiana · Recruiting

  • Baltimore VA Medical Center

    Baltimore, Maryland · Recruiting

  • MedStar Good Samaritan Hospital

    Baltimore, Maryland · Recruiting

  • Elite Research Center

    Flint, Michigan · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Palm Research Center, Inc.

    Las Vegas, Nevada · Recruiting

  • Albany Medical Center

    Albany, New York · Recruiting

  • NYC Research Inc.

    Long Island City, New York · Recruiting

  • NYU Langone Health CTSI

    New York, New York · Recruiting

  • Lucas Research Inc.

    Morehead City, North Carolina · Recruiting

  • Ohio State University Wexner Medical Center

    Columbia, Ohio · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • UPMC Presbyterian Hospital

    Pittsburgh, Pennsylvania · Recruiting

  • University Diabetes & Endocrine Consultants

    Chattanooga, Tennessee · Recruiting

  • Texas Diabetes & Endocrinology, PA

    Austin, Texas · Recruiting

  • North Texas Endocrine Center

    Dallas, Texas · Recruiting

  • Southern Endocrinology Associates

    Mesquite, Texas · Recruiting

  • Diabetes & Glandular Disease Clinic

    San Antonio, Texas · Recruiting

  • Diabetes & Endocrine Treatment Specialists

    Sandy City, Utah · Recruiting

  • University of Washington Diabetes Institute - Clinical Research Unit

    Seattle, Washington · Recruiting

  • Centricity Research Calgary Endocrinology

    Calgary, Alberta, Canada · Recruiting

  • Richmond Road Diagnostic & Treatment Centre, Clinical Trials Unit

    Calgary, Alberta, Canada · Recruiting

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.